Curated Wealth Partners LLC Sells 24,051 Shares of Biogen Inc. $BIIB

by · The Markets Daily

Curated Wealth Partners LLC decreased its position in Biogen Inc. (NASDAQ:BIIB – Free Report) by 91.3% in the 3rd quarter, HoldingsChannel reports. The institutional investor owned 2,287 shares of the biotechnology company’s stock after selling 24,051 shares during the period. Curated Wealth Partners LLC’s holdings in Biogen were worth $517,000 at the end of the most recent reporting period.

Other large investors have also bought and sold shares of the company. BlackRock Inc. acquired a new position in shares of Biogen in the 2nd quarter worth approximately $3,453,878,000. Primecap Management Co. CA bought a new position in shares of Biogen in the second quarter valued at $3,274,304,000. Legal & General Group Plc acquired a new stake in shares of Biogen during the 2nd quarter valued at $322,640,000. Bank of America Corp DE acquired a new stake in shares of Biogen during the 2nd quarter valued at $241,172,000. Finally, Deutsche Bank AG acquired a new stake in shares of Biogen during the 2nd quarter valued at $193,165,000. Institutional investors own 87.93% of the company’s stock.

Biogen Trading Down 1.1%

Shares of NASDAQ:BIIB opened at $232.65 on Friday. The firm has a fifty day moving average of $219.97 and a two-hundred day moving average of $203.85. The firm has a market capitalization of $34.37 billion, a P/E ratio of 16.85, a price-to-earnings-growth ratio of 2.61 and a beta of 0.09. Biogen Inc. has a 12-month low of $138.00 and a 12-month high of $240.99. The company has a quick ratio of 1.26, a current ratio of 1.87 and a debt-to-equity ratio of 0.39.

Biogen (NASDAQ:BIIB – Get Free Report) last posted its quarterly earnings results on Wednesday, July 29th. The biotechnology company reported $3.60 earnings per share for the quarter, topping analysts’ consensus estimates of $2.94 by $0.66. Biogen had a net margin of 8.32% and a return on equity of 11.18%. The business had revenue of $2.74 billion for the quarter, compared to the consensus estimate of $2.46 billion. During the same period in the prior year, the business posted $5.47 earnings per share. Biogen’s revenue for the quarter was up 3.4% compared to the same quarter last year. Biogen has set its FY 2026 guidance at 12.000-13.000 EPS. On average, equities analysts expect that Biogen Inc. will post 12.38 EPS for the current fiscal year.

Analyst Ratings Changes

A number of research firms have commented on BIIB. Truist Financial raised shares of Biogen from a “hold” rating to a “buy” rating and upped their price objective for the company from $190.00 to $235.00 in a research note on Monday, July 13th. Stifel Nicolaus set a $242.00 target price on shares of Biogen in a research report on Thursday, September 10th. Barclays boosted their price target on shares of Biogen from $185.00 to $200.00 and gave the company an “equal weight” rating in a report on Wednesday, July 29th. Bank of America reduced their price target on shares of Biogen from $217.00 to $215.00 and set a “neutral” rating for the company in a research report on Tuesday, July 21st. Finally, Citigroup lifted their price objective on shares of Biogen from $200.00 to $215.00 and gave the stock a “neutral” rating in a research report on Monday, August 3rd. One analyst has rated the stock with a Strong Buy rating, eighteen have given a Buy rating, twelve have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, Biogen currently has a consensus rating of “Moderate Buy” and an average target price of $236.04.

Get Our Latest Analysis on Biogen

About Biogen

(Free Report)

Biogen Inc is a biotechnology company that discovers, develops and commercializes therapies for serious neurological and neurodegenerative diseases. Its research focuses on conditions including multiple sclerosis, spinal muscular atrophy, Alzheimer’s disease, amyotrophic lateral sclerosis and rare neuromuscular disorders.

Biogen’s products include Spinraza (nusinersen) for spinal muscular atrophy, Tysabri (natalizumab) and Tecfidera (dimethyl fumarate) for multiple sclerosis, Qalsody (tofersen) for a genetically defined form of ALS, and Skyclarys (omaveloxolone) for Friedreich’s ataxia.

Featured Articles

Want to see what other hedge funds are holding BIIB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Biogen Inc. (NASDAQ:BIIB – Free Report).